CG
ADVM

Cutler Group’s Adverum Biotechnologies ADVM Stock Holding History

Cutler Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-420
Closed -$7K – 3939
2019
Q4 		$7K Sell
420
-3,920
-90% -$346K ﹤0.01% 2813
2019
Q3 		$4K Buy
+4,340
New +$489K ﹤0.01% 3120
2016
Q1 		– Sell
-2,200
Closed -$14K – 6392
2015
Q4 		$14K Buy
+2,200
New +$193K ﹤0.01% 3747

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's ADVM Position: Q1 2021 in Review

Cutler Group sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 50 shares — an estimated $5K sold.

Cutler Group first reported a position in ADVM in Q4 2015 and held it in 9 quarters. The position peaked at $41K in Q4 2019. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Cutler Group reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Cutler Group sold 50 Adverum Biotechnologies shares in Q1 2021, an estimated $5K.
  • Cutler Group first reported a position in Adverum Biotechnologies in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Adverum Biotechnologies position peaked at $41K in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.